Published in Proc Natl Acad Sci U S A on August 21, 2007
IVIG in Acute Ischemic Stroke: A Pilot Study (IVIG/AIS) | NCT01628055
Therapeutic potential of complement modulation. Nat Rev Drug Discov (2009) 1.85
Development of antihuman IgG antibodies and hematologic deficits but not clinical abnormalities in C57BL/6 mice after repeated administration of human intravenous immunoglobulin. Comp Med (2012) 1.61
Pathophysiology, treatment, and animal and cellular models of human ischemic stroke. Mol Neurodegener (2011) 1.48
Should development of Alzheimer's disease-specific intravenous immunoglobulin be considered? J Neuroinflammation (2014) 1.41
Plumbagin, a novel Nrf2/ARE activator, protects against cerebral ischemia. J Neurochem (2009) 1.39
Intravenous immunoglobulins--understanding properties and mechanisms. Clin Exp Immunol (2009) 1.34
Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke. Cell Death Dis (2013) 1.19
Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. J Neuroinflammation (2010) 1.18
Monomeric IgG is neuroprotective via enhancing microglial recycling endocytosis and TNF-alpha. J Neurosci (2008) 1.18
Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation. PLoS One (2012) 1.16
Neuroprotection in stroke by complement inhibition and immunoglobulin therapy. Neuroscience (2008) 1.16
Advances in the understanding of the mechanism of action of IVIg. J Neurol (2008) 1.15
Involvement of Fc receptors in disorders of the central nervous system. Neuromolecular Med (2009) 1.15
Complement activation in the injured central nervous system: another dual-edged sword? J Neuroinflammation (2012) 1.11
Immunoglobulin expression in non-lymphoid lineage and neoplastic cells. Am J Pathol (2009) 1.10
Toll-like receptors in cerebral ischemic inflammatory injury. J Neuroinflammation (2011) 1.06
The alternative complement pathway propagates inflammation and injury in murine ischemic stroke. J Immunol (2012) 1.03
Versatility of the complement system in neuroinflammation, neurodegeneration and brain homeostasis. Front Cell Neurosci (2014) 1.01
Reproductive age-related changes in the blood brain barrier: expression of IgG and tight junction proteins. Microvasc Res (2009) 0.99
Deficiency of complement component 5 ameliorates glaucoma in DBA/2J mice. J Neuroinflammation (2013) 0.99
Neurobiology of microglial action in CNS injuries: receptor-mediated signaling mechanisms and functional roles. Prog Neurobiol (2014) 0.94
Immunoglobulin G (IgG) attenuates neuroinflammation and improves neurobehavioral recovery after cervical spinal cord injury. J Neuroinflammation (2012) 0.92
Innate immunity and neuroinflammation. Mediators Inflamm (2013) 0.90
Advances in diagnosing and managing antibody-mediated rejection. Pediatr Nephrol (2010) 0.90
The Immune Response to Acute Focal Cerebral Ischemia and Associated Post-stroke Immunodepression: A Focused Review. Aging Dis (2014) 0.90
Intravenous immunoglobulin protects neurons against amyloid beta-peptide toxicity and ischemic stroke by attenuating multiple cell death pathways. J Neurochem (2012) 0.89
Low ficolin-3 levels in early follow-up serum samples are associated with the severity and unfavorable outcome of acute ischemic stroke. J Neuroinflammation (2011) 0.88
Complement inhibition as a proposed neuroprotective strategy following cardiac arrest. Mediators Inflamm (2010) 0.87
Complement and Antibody-mediated Enhancement of Red Blood Cell Invasion and Growth of Malaria Parasites. EBioMedicine (2016) 0.86
Neuroprotective effect of an angiotensin receptor type 2 agonist following cerebral ischemia in vitro and in vivo. Exp Transl Stroke Med (2012) 0.83
Complement in the Homeostatic and Ischemic Brain. Front Immunol (2015) 0.83
3,6'-dithiothalidomide improves experimental stroke outcome by suppressing neuroinflammation. J Neurosci Res (2013) 0.83
Role of immunoglobulin in neuronal apoptosis in a neonatal rat model of hypoxic ischemic brain injury. Exp Ther Med (2014) 0.82
Effect of high-dose intravenous immunoglobulin on anti-HLA antibodies in sensitized kidney transplant candidates. Clin Transplant (2012) 0.82
Proteomics of juvenile senegal sole (Solea senegalensis) affected by gas bubble disease in hyperoxygenated ponds. Mar Biotechnol (NY) (2008) 0.81
Treatment options and strategies for antibody mediated rejection after renal transplantation. Semin Immunol (2011) 0.81
Influence of inflammation on poststroke plasticity. Neural Plast (2013) 0.80
Intravenous immunoglobulin (IVIg) provides protection against endothelial cell dysfunction and death in ischemic stroke. Exp Transl Stroke Med (2014) 0.79
Intravenous immunoglobulin (IVIg) dampens neuronal toll-like receptor-mediated responses in ischemia. J Neuroinflammation (2015) 0.78
Highly specific inhibition of C1q globular-head binding to human IgG: a novel approach to control and regulate the classical complement pathway using an engineered single chain antibody variable fragment. Mol Immunol (2008) 0.78
IVIg attenuates complement and improves spinal cord injury outcomes in mice. Ann Clin Transl Neurol (2016) 0.77
Over-expression of DSCR1 protects against post-ischemic neuronal injury. PLoS One (2012) 0.77
Neuron-derived IgG protects neurons from complement-dependent cytotoxicity. J Histochem Cytochem (2013) 0.76
Treatment of spinal cord injury with intravenous immunoglobulin G: preliminary evidence and future perspectives. J Clin Immunol (2014) 0.76
Immunoglobulin G Expression in Human Sperm and Possible Functional Significance. Sci Rep (2016) 0.75
New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins. Ther Adv Neurol Disord (2008) 0.75
Aquaporin-4 autoantibodies increase vasogenic edema formation and infarct size in a rat stroke model. BMC Immunol (2015) 0.75
Disease-modifying effect of intravenous immunoglobulin in an experimental model of epilepsy. Sci Rep (2017) 0.75
Autoantibodies to the delta-opioid receptor function as opioid agonists and display immunomodulatory activity. J Neuroimmunol (2009) 0.75
Attenuation of Postischemic Genomic Alteration by Mesenchymal Stem Cells: a Microarray Study. Mol Cells (2016) 0.75
Deficiency of cold-inducible ribonucleic acid-binding protein reduces renal injury after ischemia-reperfusion. Surgery (2016) 0.75
Intravenous immunoglobulin and immune response. Clin Exp Immunol (2014) 0.75
Semax, an analog of ACTH(4-7), regulates expression of immune response genes during ischemic brain injury in rats. Mol Genet Genomics (2017) 0.75
Tissue kallikrein protects against ischemic stroke by suppressing TLR4/NF-κB and activating Nrf2 signaling pathway in rats. Exp Ther Med (2017) 0.75
Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke (1986) 8.23
beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci (1992) 4.10
Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. J Med Chem (1999) 2.33
Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke (2001) 2.16
Neuroprotection by the PGE2 EP2 receptor in permanent focal cerebral ischemia. Ann Neurol (2005) 1.55
Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol (2005) 1.52
Rapid induction of neutrophil-endothelial adhesion by endothelial complement fixation. Nature (1989) 1.37
Complement and apoptosis. Mol Immunol (2001) 1.35
The role of the complement cascade in ischemia/reperfusion injury: implications for neuroprotection. Mol Med (2001) 1.31
F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med (2003) 1.28
Activation of mitochondrial ATP-dependent potassium channels protects neurons against ischemia-induced death by a mechanism involving suppression of Bax translocation and cytochrome c release. J Cereb Blood Flow Metab (2002) 1.26
Comparative effect of C3a and C5a on adhesion molecule expression on neutrophils and endothelial cells. Inflammation (1996) 1.25
Activation of the complement system by recombinant tissue plasminogen activator. J Am Coll Cardiol (1987) 1.25
Structure and function of C3a anaphylatoxin. Curr Top Microbiol Immunol (1990) 1.19
Systemic fatty acid responses to transient focal cerebral ischemia: influence of neuroprotectant therapy with human albumin. J Neurochem (2002) 1.18
The effect of high-dose albumin therapy on local cerebral perfusion after transient focal cerebral ischemia in rats. Brain Res (1998) 1.13
Complement activation in the central nervous system following blood-brain barrier damage in man. Ann Neurol (1996) 1.11
Neuroprotective effect of treatment with human albumin in permanent focal cerebral ischemia: histopathology and cortical perfusion studies. Eur J Pharmacol (2001) 1.08
Assessment of neuronal viability with Alamar blue in cortical and granule cell cultures. J Neurosci Methods (1996) 1.05
Modulation of complement-mediated immune damage by intravenous immune globulin. Clin Exp Immunol (1996) 0.98
The administration of cobra venom factor reduces post-ischemic cerebral injury in adult and neonatal rats. Neurosci Lett (2005) 0.93
Pathophysiological process after transient ischemia of the middle cerebral artery in the rat. Brain Res Bull (1994) 0.88
Interplay of complement and cytokines in the pathogenesis of septic shock. Immunopharmacology (1993) 0.87
Elevated complement C3 is associated with early restenosis after eversion carotid endarterectomy. Thromb Haemost (2006) 0.84
Stroke: a vascular pathology with inadequate management. J Hypertens Suppl (2003) 0.81
Recombinant tissue plasminogen activator for acute ischemic stroke. Saudi Med J (2002) 0.80
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03
Spatio-temporal transcriptome of the human brain. Nature (2011) 9.19
Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. Science (2005) 8.86
Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell (2006) 8.09
Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1. Proc Natl Acad Sci U S A (2007) 4.62
Superoxide flashes in single mitochondria. Cell (2008) 4.08
Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci U S A (2007) 3.91
MR1 presents microbial vitamin B metabolites to MAIT cells. Nature (2012) 3.71
Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci U S A (2004) 3.61
Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke (2009) 3.55
Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science (2013) 3.45
The future of peptide-based drugs. Chem Biol Drug Des (2013) 3.41
Ageing and neuronal vulnerability. Nat Rev Neurosci (2006) 3.36
Mitochondria in neuroplasticity and neurological disorders. Neuron (2008) 3.35
Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell (2013) 3.32
Evidence that brain-derived neurotrophic factor is required for basal neurogenesis and mediates, in part, the enhancement of neurogenesis by dietary restriction in the hippocampus of adult mice. J Neurochem (2002) 3.27
Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci (2008) 3.25
AGEMAP: a gene expression database for aging in mice. PLoS Genet (2007) 3.22
Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons. Nat Neurosci (2008) 3.11
Notch promotes radioresistance of glioma stem cells. Stem Cells (2010) 3.07
Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci (2012) 2.92
Intermittent fasting dissociates beneficial effects of dietary restriction on glucose metabolism and neuronal resistance to injury from calorie intake. Proc Natl Acad Sci U S A (2003) 2.82
Herpes simplex virus-1 encephalitis can trigger anti-NMDA receptor encephalitis: case report. Neurology (2013) 2.82
"Control" laboratory rodents are metabolically morbid: why it matters. Proc Natl Acad Sci U S A (2010) 2.50
Disruption of neurogenesis by amyloid beta-peptide, and perturbed neural progenitor cell homeostasis, in models of Alzheimer's disease. J Neurochem (2002) 2.45
Diet-induced insulin resistance impairs hippocampal synaptic plasticity and cognition in middle-aged rats. Hippocampus (2008) 2.44
c-Myc is required for maintenance of glioma cancer stem cells. PLoS One (2008) 2.41
The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies. Brain Res Rev (2008) 2.39
Biological stress response terminology: Integrating the concepts of adaptive response and preconditioning stress within a hormetic dose-response framework. Toxicol Appl Pharmacol (2007) 2.37
Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc Natl Acad Sci U S A (2003) 2.35
Distal spinal and bulbar muscular atrophy caused by dynactin mutation. Ann Neurol (2005) 2.34
Alternate day calorie restriction improves clinical findings and reduces markers of oxidative stress and inflammation in overweight adults with moderate asthma. Free Radic Biol Med (2006) 2.32
Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat Neurosci (2013) 2.30
Calcium orchestrates apoptosis. Nat Cell Biol (2003) 2.27
Carcinoembryonic antigen-related cell adhesion molecule 1 inhibits MMP-9-mediated blood-brain-barrier breakdown in a mouse model for ischemic stroke. Circ Res (2013) 2.21
Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J Exp Med (2012) 2.21
Histone deacetylases as regulators of inflammation and immunity. Trends Immunol (2011) 2.18
A controlled trial of reduced meal frequency without caloric restriction in healthy, normal-weight, middle-aged adults. Am J Clin Nutr (2007) 2.16
Toll-like receptors in neurodegeneration. Brain Res Rev (2008) 2.15
GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci U S A (2009) 2.15
Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J Neurosci (2002) 2.14
Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the triple-transgenic mouse model of Alzheimer's disease. Neurobiol Dis (2007) 2.08
Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS. J Leukoc Biol (2010) 2.07
Toll-like receptor 3 inhibits memory retention and constrains adult hippocampal neurogenesis. Proc Natl Acad Sci U S A (2010) 2.05
Antigen-loaded MR1 tetramers define T cell receptor heterogeneity in mucosal-associated invariant T cells. J Exp Med (2013) 2.04
Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Exp Neurol (2007) 2.04
Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell (2011) 2.04
Acute kidney injury leads to inflammation and functional changes in the brain. J Am Soc Nephrol (2008) 2.03
Toll-like receptor signaling in neural plasticity and disease. Trends Neurosci (2011) 2.01
Cell cycle activation linked to neuronal cell death initiated by DNA damage. Neuron (2004) 1.99
Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem (2002) 1.99
Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat Med (2011) 1.97
Transient improvement in cognitive function and synaptic plasticity in rats following cancer chemotherapy. Clin Cancer Res (2006) 1.97
Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells (2009) 1.97
Caloric restriction and intermittent fasting: two potential diets for successful brain aging. Ageing Res Rev (2006) 1.94
Toll-like receptors in ischemia-reperfusion injury. Shock (2009) 1.92
Alzheimer's presenilin 1 mutations impair kinesin-based axonal transport. J Neurosci (2003) 1.91
Proteases universally recognize beta strands in their active sites. Chem Rev (2005) 1.90
Modulation of taste sensitivity by GLP-1 signaling. J Neurochem (2008) 1.89
Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer aβ oligomer bound to cellular prion protein. Neuron (2013) 1.87
Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol (2004) 1.87
Inflammatory lipid mediators in adipocyte function and obesity. Nat Rev Endocrinol (2010) 1.87
Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease. Proc Natl Acad Sci U S A (2004) 1.86
p53 in neuronal apoptosis. Biochem Biophys Res Commun (2005) 1.85
Evidence for CALM in directing VAMP2 trafficking. Traffic (2007) 1.84
Voluntary exercise and caloric restriction enhance hippocampal dendritic spine density and BDNF levels in diabetic mice. Hippocampus (2009) 1.84
Imaging cortical anatomy by high-resolution MR at 3.0T: detection of the stripe of Gennari in visual area 17. Magn Reson Med (2002) 1.83
Gamma secretase-mediated Notch signaling worsens brain damage and functional outcome in ischemic stroke. Nat Med (2006) 1.82
Structure, function and pathophysiology of protease activated receptors. Pharmacol Ther (2011) 1.81
Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders. Antioxid Redox Signal (2010) 1.77
Involvement of Notch signaling in hippocampal synaptic plasticity. Proc Natl Acad Sci U S A (2004) 1.77
Modification of brain aging and neurodegenerative disorders by genes, diet, and behavior. Physiol Rev (2002) 1.77
Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell (2011) 1.77
Neuronal and glial calcium signaling in Alzheimer's disease. Cell Calcium (2003) 1.76
Membrane properties of rat embryonic multipotent neural stem cells. J Neurochem (2004) 1.73